The global Human Fibrinogen Concentrate Market size was valued at $0.8 billion in 2023 and is projected to reach $2.9 billion by 2035, registering a CAGR of 11% from 2023 to 2035.
Human fibrinogen is a soluble plasma glycoprotein that plays a vital role in blood clot formation as a key clotting factor. Fibrinogen concentrate receives detailed attention for managing acute bleeding incidents in patients with bleeding disorders. This glycoprotein is used as a medicinal treatment for blood disorders in vertebrates, aids in clot formation. Human fibrinogens concentrate significantly improve the firmness of whole blood clots and reduces the need for postoperative transfusions in severely bleeding patients. Factors such as increase in use of fibrinogen concentrate for bleeding patients and congenital deficiency treatment are propelling the growth of the global market.
Human fibrinogens are currently used in several surgical specialties, including cardiovascular surgery, urological surgery, pulmonary surgery, wound management, orthopedic surgery, ophthalmic surgery, neurosurgery, plastic and reconstructive surgery, and dental surgery to reduce blood loss. Human fibrinogen is used for sealing tissue during surgery. Human fibrinogen helps in reducing blood loss and to stop blood flow during surgeries and in wound management. Human fibrinogens mimic the final steps of the physiological coagulation cascade to form a fibrin clot. Use of human fibrinogen can also reduce perioperative and postoperative complications by reducing fluid leakage, air leakage, and by preventing fistulae formation. Human fibrinogen has a unique physiologic action, and the resulting fibrin clot is fully degraded by the body's natural wound healing process.
The Human Fibrinogen Concentrate Market share has witnessed growth, owing to increase in geriatric population that are prone to chronic diseases, and rise in prevalence of diseases such as gastric diseases, heart attack, atherosclerosis disease, ischemic stroke, aneurysm, tumors, blood clot in brain, cancer, myocardial infarction, arrythmia, increases in blockages of blood vessel in heart, brain, kidney and liver is led to increase in number surgeries. Rise in sports injuries and road accidents is also increasing the demand for human fibrinogen products. Hence, all such factors boost the growth of the Human Fibrinogen Concentrate Market size.
For instance, according to health hearty 2020 report, the incident rate of heart attacks per 10,000 people is around 190 in people who are over 85 years of age, around 117 for those between 75-84 years of age. According to the National Center for Health Statistics, every year, more than 795,000 people in the U.S. have a stroke.
However, unfavorable reimbursements and complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers globally in the future.
Major companies operating in the market include CSL Behring GmbH, Octapharma USA, Grifols, S.A., LFB Biomedicaments, Shanghai RAAS Blood Products Co., Ltd., Takeda Pharmaceutical Company Limited, Baxter International Inc., Biotest AG, BioRad, and Harbin Pacific Biopharmaceutical Co., Ltd. Key players have adopted partnership and collaboration as their key strategy to improve the product portfolio of the Human Fibrinogen Concentrate Market.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the human fibrinogen market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global human fibrinogen market trends, key players, market segments, application areas, and market growth strategies.
Human fibrinogen is a soluble plasma glycoprotein that plays a vital role in blood clot formation as a key clotting factor. Fibrinogen concentrate receives detailed attention for managing acute bleeding incidents in patients with bleeding disorders. This glycoprotein is used as a medicinal treatment for blood disorders in vertebrates, aids in clot formation. Human fibrinogens concentrate significantly improve the firmness of whole blood clots and reduces the need for postoperative transfusions in severely bleeding patients. Factors such as increase in use of fibrinogen concentrate for bleeding patients and congenital deficiency treatment are propelling the growth of the global market.
Human fibrinogens are currently used in several surgical specialties, including cardiovascular surgery, urological surgery, pulmonary surgery, wound management, orthopedic surgery, ophthalmic surgery, neurosurgery, plastic and reconstructive surgery, and dental surgery to reduce blood loss. Human fibrinogen is used for sealing tissue during surgery. Human fibrinogen helps in reducing blood loss and to stop blood flow during surgeries and in wound management. Human fibrinogens mimic the final steps of the physiological coagulation cascade to form a fibrin clot. Use of human fibrinogen can also reduce perioperative and postoperative complications by reducing fluid leakage, air leakage, and by preventing fistulae formation. Human fibrinogen has a unique physiologic action, and the resulting fibrin clot is fully degraded by the body's natural wound healing process.
The Human Fibrinogen Concentrate Market share has witnessed growth, owing to increase in geriatric population that are prone to chronic diseases, and rise in prevalence of diseases such as gastric diseases, heart attack, atherosclerosis disease, ischemic stroke, aneurysm, tumors, blood clot in brain, cancer, myocardial infarction, arrythmia, increases in blockages of blood vessel in heart, brain, kidney and liver is led to increase in number surgeries. Rise in sports injuries and road accidents is also increasing the demand for human fibrinogen products. Hence, all such factors boost the growth of the Human Fibrinogen Concentrate Market size.
For instance, according to health hearty 2020 report, the incident rate of heart attacks per 10,000 people is around 190 in people who are over 85 years of age, around 117 for those between 75-84 years of age. According to the National Center for Health Statistics, every year, more than 795,000 people in the U.S. have a stroke.
However, unfavorable reimbursements and complications such as high costs associated with fibrin sealant products are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for fibrin sealant manufacturers globally in the future.
Major companies operating in the market include CSL Behring GmbH, Octapharma USA, Grifols, S.A., LFB Biomedicaments, Shanghai RAAS Blood Products Co., Ltd., Takeda Pharmaceutical Company Limited, Baxter International Inc., Biotest AG, BioRad, and Harbin Pacific Biopharmaceutical Co., Ltd. Key players have adopted partnership and collaboration as their key strategy to improve the product portfolio of the Human Fibrinogen Concentrate Market.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the human fibrinogen market analysis from 2023 to 2035 to identify the prevailing human fibrinogen market opportunities.The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the human fibrinogen market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global human fibrinogen market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Average Selling Price Analysis / Price Point Analysis
- Brands Share Analysis
- Criss-cross segment analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Import Export Analysis/Data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- List of customers/consumers/raw material suppliers- value chain analysis
- Market share analysis of players at global/region/country level
- Per Capita Consumption Trends
- Product Consumption Analysis
- Reimbursement Scenario
- SWOT Analysis
- Volume Market Size and Forecast
Key Market Segments
By Form
- Lyophilized
- Powder
- Liquid
By End User
- Hospitals
- Ambulatory Surgical Centers
- Others
By Indication
- Surgical Procedure
- Congenital Fibrinogen Deficiency
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- CSL Limited
- Grifols, S.A.
- Intas Pharmaceuticals Limited
- Octapharma AG
- Shanghai RAAS Blood Products Co., Ltd.
- The LFB group
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY INDICATION
CHAPTER 5: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY FORM
CHAPTER 6: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY END USER
CHAPTER 7: HUMAN FIBRINOGEN CONCENTRATE MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 280 |
Published | May 2024 |
Forecast Period | 2023 - 2035 |
Estimated Market Value ( USD | $ 0.8 billion |
Forecasted Market Value ( USD | $ 2.9 billion |
Compound Annual Growth Rate | 11.0% |
Regions Covered | Global |
No. of Companies Mentioned | 6 |